POZ

RSS

Posts tagged with "Gilead"

Aug 6
The For-Profit HIV Cure Research Crunch
A common perception in the HIV community is that the big pharma companies that make antiretrovirals (ARVs), will never pursue cure research because thier ultimate goal is to keep people living with the virus on expensive and highly profitable drugs.
But Ben Ryan’s latest exclusive shows just how much many of these companies are actually playing a major role in the search for an HIV cure.

The For-Profit HIV Cure Research Crunch

A common perception in the HIV community is that the big pharma companies that make antiretrovirals (ARVs), will never pursue cure research because thier ultimate goal is to keep people living with the virus on expensive and highly profitable drugs.

But Ben Ryan’s latest exclusive shows just how much many of these companies are actually playing a major role in the search for an HIV cure.

TAF: Will an Exciting New Gilead Drug Achieve its Full Potential?
TAF has better distribution in lymph tissues (where roughly 98 percent of HIV resides) and, at least in test tube studies, greater antiviral activity. Best of all, it can be used as a once-daily drug at doses that are roughly ten times less than that of TDF, which means that it will potentially have fewer kidney- and bone-related side effects.
For more info, click here.

TAF: Will an Exciting New Gilead Drug Achieve its Full Potential?


TAF has better distribution in lymph tissues (where roughly 98 percent of HIV resides) and, at least in test tube studies, greater antiviral activity. Best of all, it can be used as a once-daily drug at doses that are roughly ten times less than that of TDF, which means that it will potentially have fewer kidney- and bone-related side effects.

For more info, click here.

May 1
Gilead Joins Merck, ViiV in Support of HarborPath
The service provides a single point of access to HIV/AIDS medications through patient assistance programs via an online portal.

Gilead Joins Merck, ViiV in Support of HarborPath

The service provides a single point of access to HIV/AIDS medications through patient assistance programs via an online portal.

CEOs Seek End to HIV Travel Bans Worldwide
More than 40 chief executive officers from major companies have signed a pledge urging 45 countries to lift their travel restrictions on people with HIV.
Read more: http://www.poz.com/articles/unaids_ceo_pledge_1_23200.shtml

CEOs Seek End to HIV Travel Bans Worldwide

More than 40 chief executive officers from major companies have signed a pledge urging 45 countries to lift their travel restrictions on people with HIV.

Read more: http://www.poz.com/articles/unaids_ceo_pledge_1_23200.shtml

Stribild, the once-daily four-in-one fixed-dose combination (FDC) tablet formerly known as the “Quad,” has been approved for people living with HIV initiating antiretroviral (ARV) therapy for the first time, according to announcements by Gilead Sciences and the U.S. Food and Drug Administration released on Monday, August 27.

Stribild, the once-daily four-in-one fixed-dose combination (FDC) tablet formerly known as the “Quad,” has been approved for people living with HIV initiating antiretroviral (ARV) therapy for the first time, according to announcements by Gilead Sciences and the U.S. Food and Drug Administration released on Monday, August 27.

FDA Gives Priority Review of Truvada as PrEP

The U.S. Food and Drug Administration (FDA) has accepted Gilead Sciences’ application to give priority review of Truvada (emtricitabine and tenofovir) as pre-exposure prophylaxis (PrEP), according to a Gilead statement. This PrEP is when an HIV-negative person takes a daily dose of Truvada as a means to lower the chance of contracting the virus during sex. The FDA grants fast-track appraisal to drug applicants that demonstrate major advances in treatment or provide a treatment where no adequate or current therapy exists. Approval of the supplemental New Drug Application (sNDA) will be discussed at the FDA Antiviral Drugs Advisory Committee in May. The target review date is June 15. 

(Source: poz.com)

From the Newsfeed: New Three-in-One HIV Med Complera Approved

CompleraComplera, a complete single-tablet regimen containing Janssen Therapeutics’ Edurant (rilpivirine) and Gilead Sciences’ Viread (tenofovir) and Emtriva (emtricitabine), was approved August 10 by the U.S. Food and Drug Administration (FDA), according to an announcement by Gilead. Complera, the second all-in-one fixed-dose combination tablet for people living with HIV, is approved for those starting antiretroviral (ARV) therapy for the first time.

This is big news, huge news. Have questions? Ask us.